Targeting Noncoding cis -Regulatory Elements for Cancer Therapy in the Context of the 3D Genome
- 1 November 2024
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (11) , 2061-2065
Abstract
Summary: Significant efforts have been made to identify and validate oncoproteins and ncRNAs as therapeutic targets for cancer therapy; however, emerging observations suggest that noncoding cis-regulatory elements, which orchestrate the 3D organization of the genome and thus the transcriptional landscape, are potential therapeutic targets as well. In this commentary, we envisage that further efforts to decipher the noncoding cis-regulatory code and performing systematic surveys of functional noncoding cis-regulatory elements and recurrent 3D genome alterations in both cancerous and nonmalignant cells within tumor tissues will pave the way to the development of novel therapeutic strategies.Keywords
This publication has 15 references indexed in Scilit:
- TULIPs decorate the three-dimensional genome of PFA ependymomaCell, 2024
- Genome-wide Cas9-mediated screening of essential non-coding regulatory elements via libraries of paired single-guide RNAsNature Biomedical Engineering, 2024
- Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancerThe Lancet Oncology, 2024
- Extrachromosomal DNA in cancerNature Reviews Cancer, 2024
- Deciphering the multi-scale, quantitative cis-regulatory codeMolecular Cell, 2023
- Subtype-specific 3D genome alteration in acute myeloid leukaemiaNature, 2022
- Characterizing cis-regulatory elements using single-cell epigenomicsNature Reviews Genetics, 2022
- Structural variations in cancer and the 3D genomeNature Reviews Cancer, 2022
- A new era in functional genomics screensNature Reviews Genetics, 2021
- Non-coding driver mutations in human cancerNature Reviews Cancer, 2021